View in EDS HTML Full Text PDF Full Text

Venlafaxine in children and adolescents with attention deficit hyperactivity disorder.

Saved in:
Bibliographic Details
Title: Venlafaxine in children and adolescents with attention deficit hyperactivity disorder.
Authors: MOTAVALLI MUKADDES, NAHIT (AUTHOR), ABALI, OSMAN (AUTHOR)
Source: Psychiatry & Clinical Neurosciences. Feb2004, Vol. 58 Issue 1, p92-95. 4p.
Subjects: Venlafaxine, Treatment of attention-deficit hyperactivity disorder, Adolescent psychopathology, Attention-deficit hyperactivity disorder, Children with attention-deficit hyperactivity disorder, Child psychopathology, Mental illness
Abstract: The primary purpose of this study was to describe tolerability and efficacy of venlafaxine in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). A 6-week open trial of venlafaxine was conducted in 13 children and adolescents (mean age 9.9 ± 2.5 years) with ADHD, and without comorbid depression. Venlafaxine was initiated at a dose of 18.75 mg/day and flexibly titrated to 56.25 mg/day. The Conners parent scale and Clinical Global Improvement (CGI) severity item were performed at baseline and at the end of the 6-week trial. All subjects completed the trial. Mean final dose of venlafaxine was 40.3 ± 7.0. Venlafaxine was significantly effective in reducing the total score of the Conners parent scale from baseline to endpoint ( P < 0.002, Z =−3.113) and the CGI severity item ( P < 0.05). Transient side-effects such as somnolence ( n = 2), stomachache ( n = 2), and headache ( n = 1) disappeared after second week of treatment. Also three subjects complained of sedation after raising the dose to 56.5 mg/day, therefore the dose was reduced to the previous level. These preliminary data suggest that venlafaxine may be an effective medication in the treatment of some children and adolescents with ADHD. Future double-blind controlled trials should be undertaken. [ABSTRACT FROM AUTHOR]
Copyright of Psychiatry & Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 11713641
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Venlafaxine in children and adolescents with attention deficit hyperactivity disorder.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22MOTAVALLI+MUKADDES%2C+NAHIT%22&quot;&gt;MOTAVALLI MUKADDES, NAHIT&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22ABALI%2C+OSMAN%22&quot;&gt;ABALI, OSMAN&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Psychiatry+%26+Clinical+Neurosciences%22&quot;&gt;Psychiatry &amp; Clinical Neurosciences&lt;/searchLink&gt;. Feb2004, Vol. 58 Issue 1, p92-95. 4p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Venlafaxine%22&quot;&gt;Venlafaxine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Treatment+of+attention-deficit+hyperactivity+disorder%22&quot;&gt;Treatment of attention-deficit hyperactivity disorder&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Adolescent+psychopathology%22&quot;&gt;Adolescent psychopathology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Attention-deficit+hyperactivity+disorder%22&quot;&gt;Attention-deficit hyperactivity disorder&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Children+with+attention-deficit+hyperactivity+disorder%22&quot;&gt;Children with attention-deficit hyperactivity disorder&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Child+psychopathology%22&quot;&gt;Child psychopathology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Mental+illness%22&quot;&gt;Mental illness&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The primary purpose of this study was to describe tolerability and efficacy of venlafaxine in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). A 6-week open trial of venlafaxine was conducted in 13 children and adolescents (mean age 9.9 &#177; 2.5 years) with ADHD, and without comorbid depression. Venlafaxine was initiated at a dose of 18.75 mg/day and flexibly titrated to 56.25 mg/day. The Conners parent scale and Clinical Global Improvement (CGI) severity item were performed at baseline and at the end of the 6-week trial. All subjects completed the trial. Mean final dose of venlafaxine was 40.3 &#177; 7.0. Venlafaxine was significantly effective in reducing the total score of the Conners parent scale from baseline to endpoint ( P &lt; 0.002, Z =−3.113) and the CGI severity item ( P &lt; 0.05). Transient side-effects such as somnolence ( n = 2), stomachache ( n = 2), and headache ( n = 1) disappeared after second week of treatment. Also three subjects complained of sedation after raising the dose to 56.5 mg/day, therefore the dose was reduced to the previous level. These preliminary data suggest that venlafaxine may be an effective medication in the treatment of some children and adolescents with ADHD. Future double-blind controlled trials should be undertaken. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Psychiatry &amp; Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=11713641
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/j.1440-1819.2004.01199.x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 4
        StartPage: 92
    Subjects:
      – SubjectFull: Venlafaxine
        Type: general
      – SubjectFull: Treatment of attention-deficit hyperactivity disorder
        Type: general
      – SubjectFull: Adolescent psychopathology
        Type: general
      – SubjectFull: Attention-deficit hyperactivity disorder
        Type: general
      – SubjectFull: Children with attention-deficit hyperactivity disorder
        Type: general
      – SubjectFull: Child psychopathology
        Type: general
      – SubjectFull: Mental illness
        Type: general
    Titles:
      – TitleFull: Venlafaxine in children and adolescents with attention deficit hyperactivity disorder.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: MOTAVALLI MUKADDES, NAHIT
      – PersonEntity:
          Name:
            NameFull: ABALI, OSMAN
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2004
              Type: published
              Y: 2004
          Identifiers:
            – Type: issn-print
              Value: 13231316
          Numbering:
            – Type: volume
              Value: 58
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Psychiatry & Clinical Neurosciences
              Type: main
ResultId 1